ROIV Financials

Income Statement
MetricQ2 2027Q1 2027Q4 2026Q3 2026Q2 2026
Revenue
35.1M
+2335.6%
1.4M
-42.8%
2.5M
+26.1%
2.0M
+27.2%
1.6M
Cost of Revenue
3.3M
0
0
0
-100.0%
111.0K
Gross Profit
31.8M
+2103.5%
1.4M
-42.8%
2.5M
+26.1%
2.0M
+36.9%
1.5M
Operating Expenses
299.8M
-18.4%
367.4M
+189.0%
-412720000
-221.0%
341.2M
+10.9%
307.7M
R&D
145.7M
-27.9%
202.0M
+1.5%
198.9M
+20.3%
165.4M
+0.5%
164.6M
SG&A
154.1M
-6.9%
165.5M
+4.6%
158.3M
-9.6%
175.1M
+22.3%
143.1M
Operating Income
-268049000
+26.8%
-365993000
-188.1%
415.2M
+222.4%
-339153000
-10.7%
-306233000
EBITDA
-267445000
+26.9%
-365785000
-3.2%
-354357000
-4.7%
-338462000
-10.9%
-305312000
Net Income
-137211000
+52.8%
-290606000
-181.7%
355.7M
+213.4%
-313701000
-88.9%
-166039000
EPS (Basic)
$-0.27
-3.8%
$-0.26
-161.9%
$0.42
+210.5%
$-0.38
-123.5%
$-0.17
EPS (Diluted)
$-0.27
-3.8%
$-0.26
-161.9%
$0.42
+210.5%
$-0.38
-123.5%
$-0.17
Shares (Diluted)
722.8M
+0.3%
720.8M
+0.5%
717.4M
+2.9%
696.9M
+2.3%
680.9M
Roivant Sciences Ltd. Common Shares (ROIV) — Financials